
Galderma's Restylane Shaype was approved in Mexico for temporary chin augmentation and improved jawline definition, the company announced on November 13, 2026.
This is Restylane Shaype's first international regulatory approval for jawline treatment, further expanding its portfolio offerings as the pure-play dermatology category leader.
Related: Galderma Launches ALASTIN Restorative Eye Complex Featuring TriHex+™ Technology
The move also expands its availability for chin augmentation to Mexico, which is already approved across various markets globally, including Europe, Brazil, Canada and Thailand.
The approval signals growing interest in jawline contouring, as factors such as aging can contribute to changes in fat layers, which can result in tissue descent and jowling.
The announcement also follows recent market research conducted by Galderma, which finds that the chin is the third most treated area in existing HA injectable users.

Data in the jawline has also shown that Restylane Shaype was superior to no-treatment for restoring and enhancing jawline definition, with durable improvements maintained for up to two years. 70% of patients reported improved overall satisfaction with their appearance and 82% noted the natural-looking results of the long-lasting treatment option. A further study of Restylane Shaype for the jawline shows over 92% would recommend the treatment to a friend and over 90% would choose to receive the treatment again.
“In my practice, I see many patients who are looking for effective, long-lasting facial enhancements to address their concerns around structure and facial balance. Having new innovations in injectable treatments that allow us to address these concerns with precision while maintaining natural-looking results is incredibly valuable. Restylane Shaype represents an exciting development for the field, combining a bone-mimicking hyaluronic acid gel with clinical evidence that demonstrates sustained, yet temporary, improvements in facial structure and definition,” said Dr. Osvaldo Vazquez, the CEO of Skin Group.
For medspa owners and injectors, the news signals growing patient interest in the lower face, which plays a pivotal role in overall facial balance and influences proportions and profile. It also speaks to the influence of medication-driven weight loss and its effect on facial fat distribution.










